Table 4.

Safety outcomes by renal impairment subgroup

N (%)
CrCL, mL/min
≥15 to <5050 to <80≥80
Kd56 (n = 85)Vd (n = 97)Kd56 (n = 186)Vd (n = 174)Kd56 (n = 192)Vd (n = 185)
Median duration of treatment, wk362150275231
 IQR18-6812-3425-8715-4526-10317-60
Median n of cycles received971281310
 IQR4-174-116-215-137-256-19
Patients with AEs leading to carfilzomib or bortezomib discontinuation27 (31.8)23 (23.7)47 (25.3)41 (23.6)46 (24.0)38 (20.5)
Treatment-emergent grade ≥3 AEs of interest*
 Hypertension12 (14.1)3 (3.1)27 (14.5)7 (4.0)30 (15.6)5 (2.7)
 Peripheral neuropathy04 (4.1)5 (2.7)16 (9.2)1 (0.5)8 (4.3)
 Dyspnea8 (9.4)2 (2.1)12 (6.5)2 (1.1)9 (4.7)6 (3.2)
 Cardiac failure4 (4.7)07 (3.8)1 (0.6)3 (1.6)2 (1.1)
 Acute kidney injury3 (3.5)2 (2.1)4 (2.2)2 (1.1)5 (2.6)3 (1.6)
Grade ≥2 peripheral neuropathy*014 (14.4)13 (7.0)36 (20.7)5 (2.6)34 (18.4)
  • AEs were not adjusted for exposure.

  • IQR, interquartile range.

  • * Preferred term.